Information Provided By: 
Fly News Breaks for December 17, 2019
ALNY
Dec 17, 2019 | 12:10 EDT
Piper Jaffray analyst Edward Tenthoff maintained an Overweight rating on Alnylam Pharmaceuticals and raised his price target on the shares to $155 from $145 after the company reported "positive" Phase III ILLUMINATE-A data on lumasiran in primary hyperoxaluria type 1. Tenthoff said he is "confident" in the treatment getting approval in the U.S. by year end 2020 and in Europe in 2021 and he forecasts lumasirin sales of $8M in 2020 and $85M in 2021. The analyst also noted that ONPATTRO and GIVLAARI launches are "progressing" to drive 2020 sales.
News For ALNY From the Last 2 Days
There are no results for your query ALNY
